Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
07. August 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
06. August 2024 08:00 ET
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
30. Mai 2024 08:00 ET
|
Compass Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
25. April 2024 08:00 ET
|
Compass Therapeutics
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
16. April 2024 08:00 ET
|
Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12. April 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
10. April 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
28. Februar 2024 08:00 ET
|
Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19. April 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
09. September 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...